Efficacy of Histidine–Tryptophan–Ketoglutarate Solution Versus Blood Cardioplegia in Cardiac Surgical Procedures: A Randomized Controlled | Parallel Group Study
DOI:
https://doi.org/10.1532/hsf.3495Keywords:
Blood cardioplegia, cardiac procedures , HTK solution, CustodiolAbstract
Background: In cardiac surgery, myocardial protection is required during cross-clamping followed by reperfusion. The use of cardioplegic solutions helps preserve myocardial energy stores, hindering electrolyte disturbances and acidosis during periods of myocardial ischaemia. This study aimed to compare the efficacy and safety between the histidine–tryptophan–ketoglutarate (HTK) solution and blood cardioplegia in various cardiac surgeries.
Methods: Three-hundred-twenty patients aged 30-70 years old undergoing various cardiac surgeries were randomized into the HTK group and the blood cardioplegia group. The ventilation time, total bypass time, cross-clamp time, length of intensive care unit (ICU) or hospital stay, and postoperative complications were analyzed.
Results: The total bypass time and cross-clamp time were significantly shorter in the HTK group than in the blood cardioplegia group (P < 0.001). Segmental wall motion abnormalities (SWMA) at postoperative echocardiography were significantly higher in in the blood cardioplegia group (P = 0.008). The number of patients requiring DC Shock was significantly higher in the HTK group (P < 0.001). The number of patients requiring inotropic support was significantly higher in the blood cardioplegia group (P < 0.001). The length of ICU, hospital stay, and ventilation time were significantly longer in the blood cardioplegia group than in the HTK group (P = 0.004, P < 0.001, P < 0.001, respectively). The number of patients requiring prolonged ventilation was significantly higher in the blood cardioplegia group compared with the HTK group (P = 0.022). There was no significant difference between the study groups regarding electrocardiographic changes, 30-day mortality, and 30-day readmission.
Conclusion: The use of HTK cardioplegia was associated with significantly shorter cross-clamp time, bypass time, duration of mechanical ventilation, length of ICU stay, and length of hospital stay. It is associated with less incidence of postoperative segmental wall abnormalities and less need for inotropic support than blood cardioplegia. Custodiol cardioplegia is a safe and feasible option that can be used as an effective substitute for blood cardioplegia to enhance myocardial protection.
References
Ali AS, Ataa SA, Moftahb HM, El Ghanamb MA, Eldin Moustafab MG. 2019. A comparative study between custodiol and warm blood cardioplegia in coronary artery bypass graft operation with poor left ventricular function. J Med Sci Res. 2:132-6.
Bojan M, Peperstraete H, Lilot M, Tourneur L, Vouhé P, Pouard P. 2013. Cold histidine-tryptophan-ketoglutarate solution and repeated oxygenated warm blood cardioplegia in neonates with arterial switch operation. Ann Thorac Surg. 95:1390-6.
Braathen B, Jeppsson A, Scherstén H, et al. 2011. One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study. J Thorac Cardiovasc Surg. 141:995-1001.
Careaga G, Salazar D, Téllez S, Sánchez O, Borrayo G, Argüero R. 2001. Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res. 32:296-9.
Fannelop T, Dahle GO, Salminen PR, et al. 2009. Multidose cold oxygenated blood is superior to a single dose of Bretschneider HTK-cardioplegia in the pig. Ann Thorac Surg. 87(4):1205-1213.
Hachida M, Nonomyama M, Bonkohara Y, Hanayama N, Saitou S, Maeda T. 1997. Clinical Assessment of Prolonged Myocardial Preservation for Patients with a Severely Dilated Heart. Ann Thorac Surg. Jul;64(1):59-63.
Hamed MA, Abdelghaffar RA. 2018. Comparative study between three solutions for cardioplegia in pediatric cardiac surgery: histidine-tryptophan-ketoglutarate (HTK) solution, blood cardioplegia and crystalloid (St. Thomas) cardioplegia. J Anesth Clin Res. 9:818.
Huang JB, Liu YL, Yu CT, et al. 2011. Lung biopsy findings in previously inoperable patients with severe pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 151:76-83.
Ishikawa S, Ueda K, Neya K, et al. 2010. Effects of original crystalloid cardioplegia followed by additional blood cardioplegia: treatments for prolonged cardiac arrest. Ann Thorac Cardiovasc Surg. 16: 335-9.
Korun O, Özkan M, Terzi A, Aşkın G, Sezgin A, Aşlamacı S. 2013. The comparison of the effects of Bretschneider's histidine-tryptophan ketoglutarate and conventional crystalloid cardioplegia on pediatric myocardium at tissue level. Artif Organs. 37:76-81.
Liu J, Feng Z, Zhao J, Li B, Long C. 2008. The myocardial protection of HTK cardioplegic solution on the long-term ischemic period in pediatric heart surgery. ASAIO J. 54:470-3.
Mahrous R, Abo El-Ela A, Mukhtar A, et al. 2016. A comparative study for the efficacy of blood cardioplegia versus histidine-tryptophan-ketoglutarate (HTK) cardioplegia in pediatric patients undergoing total corrective cardiac surgery. Med J Cairo Univ. r:389-95.
Nardi P, Vacirca SR, Russo M, et al. 2018. Cold crystalloid versus warm blood cardioplegia in patients undergoing aortic valve replacement. J Thorac Dis. 10:1490-9.
Pizano A, Montes FR, Carreno M, Echeverri D, Umana JP. 2018. Histidine- Triptophan, Ketoglutalate solution versus blood cardioplegia in cardiac surgery: A propensity- score matched analysis. The Heart Surgery Forum. 21(3): 158-164.
Prathanee S, Kuptanond C, Intanoo W, Wongbhudha C, Karunasumaeta C. 2015. Custodiol-HTK solution for myocardial protection in CABG patients. J Med Assoc Thai. 98:164-7.
Preusse CJ, Gebhard MM, Bretschneider HJ. 1981. Myocardial “equilibration processes” and myocardial energy turnover during initiation of artificial cardiac arrest with cardioplegic solution - reasons for a sufficiently long cardioplegic perfusion. Thorac Cardiovasc Surg. 29:71-6.
Saitoh Y, Hashimoto M, Ku K, et al. 2000. Heart preservation in HTK solution: role of coronary vasculature in recovery of cardiac function. Ann Thorac Surg. 69:107-12.
Sakata J, Morishita K, Ito T, Koshino T, Kazui T, Abe T. 1998. Comparison of clinical outcome between histidine-tryptophan-ketoglutarate solution and cold blood cardioplegic solution in mitral valve replacement. J Card Surg. 13:43-7.
Takeuchi K, Akimoto H, Maida K, Munakata M, Fukui K, Daitoku K, Takaya S, Suzuki S, Tabayashi K, Tanaka S. 2002. Myocardial Protection of the Pressure Overload Hypertrophied Heart in Human Cardiac Surgery by Acceleration of Anaerobic Glycolysis. J Cardiovasc surg (Torino). Feb;43(1):37-41.
Viana FF, Shi WY, Hayward PA, Larobina ME, Liskaser F, Matalanis G. 2013. Custodiol versus blood cardioplegia in complex cardiac operations: an Australian experience. Eur J Cardiothorac Surg. 43:526-31.
Von Oppell UO, Pfeiffer S, Preiss P, Dunne T, Zilla P, Reichart B. 1990. Endothelial cell toxicity of solid-organ preservation solutions. Ann Thorac Surg. 50(6):902-910.
Weisel RD. 2013. Blood or crystalloid cardioplegia: which is better? Eur J Cardiothorac Surg. 43:532-3.
Yang Q, Zhang RZ, Yim AP, He GW. 2004. Histidine-tryptophan-ketoglutarate solution maximally preserves endothelium-derived hyperpolarization factor mediated function during heart preservation: comparison with University of Wisconsin solution. J Heart Lung Transpl. 26:352-9
